Neoprobe to Present at Healthcare Conference

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present on Monday, January 7, 2008 at 1:30 PM PST (4:30 PM EST) during the OneMedPlace Emerging Healthcare Companies and Technologies Finance Forum to be held at the Sir Francis Drake Hotel in San Francisco. Mr. Bupp’s presentation will provide an overview of the company’s technology, development activities and business prospects.

Interested parties can access an archived internet broadcast of the presentation starting on Friday, January 11th at: www.onemedplace.com

The archived presentation will be available after Friday, January 11, 2008.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.www.neoprobe.com